SGLT2i and AF

31 August 2025 (08:30 - 08:45)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Doctor Jamschid Sedighi

Justus-Liebig University of Giessen, Giessen (Germany)

5 More presentations in this session

Presentation thumbnail

CONFIDENCE: Results by KDIGO risk category

Doctor M. Vaduganathan (Boston, US)

Presentation thumbnail

SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction

Professor M. Mamas (Keele, GB)

Presentation thumbnail

Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice

Ms L. Wilson (US)

Presentation thumbnail

STRIDE Outcomes by Sexl

Professor S. Verma (Toronto, CA)

Presentation thumbnail

Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction

Doctor N. Kruger (Boston, US)

Access the full session

Session thumbnail

Late-Breaking Clinical Science: cardiometabolic medicine

The Event

Event poster

ESC Congress 2025

31 August 2025 08:30 CET

You may be interested in

Congress Session

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Congress Presentation

Can SGLT2i use decrease the risk of atrial fibrillation in patients with heart failure with reduced ejection fraction: a retrospective cohort study

Congress Session

Integrated management of atrial fibrillation: addressing comorbidities, risk factors, and lifestyle

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources